Dual acting anti-inflammatory drugs: A reappraisal

Pharmacological Research

Volumn 44, Issue 6, 2001, Pages 437-450

  Bertolini, A ^a   Ottani, A ^a   Sandrini, M ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

5 lipoxygenase; Cyclooxygenases; Dual acting anti inflammatory drugs; NSAIDs; NSAIDs toxicity; Osteoarthritis; Specific COX 2 inhibitors

Indexed keywords

1 (7 TERT BUTYL 2,3 DIHYDRO 3,3 DIMETHYLBENZO[B]FURAN 5 YL) 4 CYCLOPROPYL 1 BUTANONE; 2 (3 PYRIDYLMETHYL)INDAZOLINONE; 3 AMINO 1 (3 TRIFLUOROMETHYLPHENYL) 2 PYRAZOLINE; 4 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 2 METHYL 1,2 OXAZIN 3 ONE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ALPHA METHYL 6 (2 QUINOLYLMETHOXY) 2 NAPHTHYLACETIC ACID; ALPHA PENTYL 3 (2 QUINOLYLMETHOXY)BENZYL ALCOHOL; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; ATRELEUTON; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; IBUPROFEN; LEUKOTRIENE; LICOFELONE; LIPOXYGENASE INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N [5 (4 FLUOROPHENOXY) 2 THIENYL]METHANESULFONAMIDE; NAPROXEN; NIMESULIDE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; ROFECOXIB; TEPOXALIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; BLOOD VESSEL PERMEABILITY; CHEMOTAXIS; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME INHIBITION; HEART PROTECTION; HUMAN; INFLAMMATION; KIDNEY INJURY; NONHUMAN; OSTEOARTHRITIS; PAIN; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW; RHEUMATIC DISEASE; SIGNAL TRANSDUCTION; STOMACH INJURY; STOMACH PROTECTION;

EID: 0035662474     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2001.0872     Document Type: Article

References (127)

1. Management of osteoarthritis in the primary-cause setting: An evidence-based approach to treatment
2. Why do we need treatments for rheumatoid arthritis
3. Anti-inflammatory drugs and their mechanism of action
4. Rofecoxib
5. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy
6. General pharmacology of (2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine)-acetic acid in experimental animals
7. Novel nonsteriodal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat
8. Nitric oxide and inflammation arthritides
9. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenases
10. Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation
11. Selective COX-2 inhibitors: Is the water becoming muddy?
12. Eicosanoid nomenclature
13. Cellular responses to eicosanoids: Molecular biology of eicosanoid receptors
14. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs
15. Nonsteroidal anti-inflammatory drugs: Differences and similarities
16. Prostaglandin and thromboxane biosynthesis
17. 2 synthase in human monocytes
18. Expression of a nitrogen-responsiveness gene encoding prostaglandin synthase is regulated by mRNA splicing
19. TIS10, a phorbol ester tumour promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
20. 2 synthase-1
21. 523 to Val mutation
22. Investigation of the binding of isoform-selective inhibitors to endoperoxide synthase using fluorescence spectroscopy
23. COX-2 inhibitors
24. Cyclooxygenase-2 inhibitors: Discovery and future
25. Prostanoids as regulators of gastrointestinal function
26. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications
27. Expression of a nitrogen-inducible cyclooxygenase in brain neurons. Regulation by synaptic activity and glucocorticoids
28. Characterisation of inducible cyclooxygenase in the rat brain
29. Prostaglandin H synthase-2 in human gestational tissues: Regulation in amnion
30. Development expression of the cyclooxygenase-1 and cyclooxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids
31. Involvement of tyrosine kinase in the induction of cyclooxygenase and nitric oxide synthase by endotoxin in cultured cells
32. Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages
33. Up-regulation of inducible cyclooxygenase gene expression by platelet-activating factor in activated rat alveolar macrophages
34. Characterisation of cyclooxygenase-1 and -2 expression in mouse resident peritoneal macrophages in vitro: Interactions of non steroidal anti-inflammatory drugs with COX2
35. 2 stimulation
36. Expression of prostaglandin endoperoxide synthase-1 and prostaglandin endoperoxide synthase-2 in human
37. Induction of cyclooxygenase II in human synovial microvessel endothelial cells by interleukin-1
38. Regulation of cyclooxygenase and thromboxane synthase in human monocytes
39. 2-isoprostane formation
40. Selective expression of nitrogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide
41. Inhibition by interleukin-10 inducible cyclooxygenase expression in lipopolysaccharide-stimulated monocytes: Its underlying mechanism in comparison with interleukin-4
42. LPS-dependent cyclooxygenase-2 induction in human monocytes is down regulated by IL-13, but not by IFN-γ
43. Mechanism of action of nonsteroidal anti-inflammatory drugs
44. Clinical experience with cyclooxygenase-2 inhibitors
45. Differential inhibition of COX1 and COX2 by NSAIDs: A summary of results obtained using various test systems
46. Activity of nimesulide on inducible cyclooxygenase
47. Meloxicam
48. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs
49. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1
50. NSAIDs, COX2 inhibitors, and the gut
51. Effect of nabumetone on prostanoids synthesis in humans
52. Selective cyclooxygenase-2 inhibitors: Pharmacology, clinical effects and therapeutic potential
53. Interpreting the clinical significance of differential inhibition of cyclooxyenase-1 and cyclooxygenase-2
54. Specific COX-2 inhibitors: From bench to bedside
55. Outcome of specific COX-2 inhibition in rheumatoid arthritis
56. Preliminary study of the safety and efficacy of SC-8635, a novel cyclooxygenase-2 inhibitor
57. Efficacy, tolerability, and safety of celecoxib, a specific COX-2 inhibitor, in osteoarthritis
58. Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in rheumatoid arthritis
59. Systemic biosynthesis of prostacyclin cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
60. A pilot endoscopic study of gastroduodenal effects of SC58635, a novel COX-2 inhibitor
61. Demonstration of specific Cox-2 inhibition by MK966 (Vioxx) in humans with supratherapeutic doses
62. Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
63. Characterisation of rofecoxib as a cyclooxygenase 2 isoform inhibitor and demonstration of analgesia in the dental pain model
64. MK-0966, a specific COX-2 inhibitor has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis in 26-week controlled clinical trial
65. Characterisation of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey and human gastrointestinal tract
66. COX-1 expression in human gastric mucosa infected with Helicobacter pylori: Constitutive or induced?
67. Increased inducible cyclooxygenase associated with treatment failure in ulcerative colitis
68. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2
69. Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice
70. Effect of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastrointestinal ulcer model in rats
71. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs
72. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs
73. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and non-human primate stomach
74. Inducible cyclooxygenase may have anti-inflammatory properties
75. COX-1, COX-2 and COX-3 and the future treatment of chronic inflammatory disease
76. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
77. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
78. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
79. Effects of some naturally occurring prostanoids and some cylooxygenase inhibitors on the contraction of the human uterine segment in vivo
80. Hypoxia induces cyclooxygenase-2 via NF-KappaB pbs transcription factors in human endothelial cells
81. Cyclooxygenase-1 contributes to inflammatory response in rats and mice: Implications for gastrointestinal toxicity
82. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain
83. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
84. 2 formation in tissue from human colonic mucosa and chronic bursitis
85. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis
86. IL-2 gene expression and NF-kappa B activation through CD28 requires reactive oxygen production by 5-lipoxygenase
87. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis
88. Why do we need treatments for rheumatoid arthritis
89. Animal models of rheumatoid arthritis. Clues to etiology and treatment
90. Leukotrienes
91. Lipid mediators in inflammatory disorders
92. Role of leukotrienes on coronary vasoconstriction in isolated hearts of arthritic rats: Effect of in vivo treatment with CI-986, a dual inhibitor of cyclooxygenase and lipoxygenase
93. Designing therapeutically effective 5-lipoxygenase inhibitors
94. The effects of 5-lipoxygenase inhibitors and leukotriene antagonists on the development of gastric lesions induced by nonsteroidal antiinflammatory drugs in mice
95. Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damage
96. 5-Lipoxygenase: A target for antiinflammatory drugs revisited
97. Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity
98. 5-Lipoxygenase inhibitory activity of zileuton
99. Acetohydroxamic acids as potent, selective, orally active 5-lipoxygenase inhibitors
100. (Methoxyalkyl)thiazoles: A new series of potent, selective, and orally active 5-lipoxygenase inhibitors displaying high enantioselectivity
101. Methoxyalkyl thiazoles: A novel series of potent, orally active and enantioselective inhibitors of 5-lipoxygenase
102. Conversion of a cyclooxygenase (CO) inhibitor into a 5-lipoxygenase (LO) inhibitor: A general route to novel orally active anti-inflammatory and anti-allergy drugs
103. The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma
104. Treatment of chronic stable asthma with drugs active on the 5-lipoxygenase pathway
105. Cysteinyl leukotrienes in asthma: Old mediators up to new tricks
106. Mode of action of anti-inflammatory agents which are prostaglandin synthetase inhibitors
107. Prostaglandin modulation of mast cell-dependent inflammation
108. Eicosanoids as mediators and modulators of inflammation
109. Tepoxalin inhibits prostaglandin and leukotriene production in adjuvant arthritic rats and in dog knee joints challenged with sodium-urate and immune complex
110. Tissue-selective inhibition of prostaglandin synthesis in rat by tepoxalin: Anti-inflammatory without gastropathy
111. Gastrointestinal profile of tepoxalin, an orally active dual cyclooxygenase and lipoxygenase inhibitor with potent anti-inflammatory activity
112. New cyclooxygenase-2/5-lipoxygenase inhibitors. 1. 7-Tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: Discovery and variation of the 5-keto substituent
113. Effect of tebufelone (NE-11740), a new anti-inflammatory drug, on arachidonic acid metabolism
114. Antipyretic activity of tebufelone (NE-11740) in man
115. New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-Tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: Variations of the dihydrobenzofuran ring
116. New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-Tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: Variations at the 5 position
117. Single-dose pharmacokinetics and dose proportionality of the antiinflammatory drug, CI-1004, in healthy subjects
118. Multiple-dose pharmacokinetics of the antiinflammatory drug, CI-1004, in healthy subjects after 3-weeks of once-daily dosing
119. Antiarthritic profile of BF-389, a novel anti inflammatory agent with low ulcerogenic liability
120. RWJ 63556, a potent orally active dual 5-LO/COX-2 inhibitor: In vitro and in vivo pharmacology
121. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation
122. Analysis of a novel antiinflammatory agent, 1-(7-tert-butyl-2,3-dihydro3,3-dimethylbenzo(b)furan-5-yl)-4- cyclopylbutan-1-one (PGV-20229), in plasma matrices by stable-isotope-dilution gas chromatography-mass spectrometry
123. (6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase
124. Pharmacological profile of a new pyrrolozine derivative inhibiting the enzymes cyclooxygenase and 5-lipoxygenase
125. ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury
126. Acute and chronic anti-inflammatory properties of (2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl)- acetic acid